62426
document
Remission in rheumatoid arthritis patients treated with etanercept monotherapy : clinical practice and clinical trial experience . OBJECTIVES To assess , in a randomised controlled trial ( RCT ) and in clinical practice , an association of time to remission and baseline disease activity with both induction of remission and sustained remission in etanercept-treated patients with rheumatoid arthritis ( RA ) . METHODS Data from an RCT ( Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes [ TEMPO ] ; n=682 ) and an observational registry ( Rheumatoid Arthritis DMARD Intervention and Utilization Study [ RADIUS II ] ; n=4341 ) were used to evaluate disease activity ( Clinical Disease Activity Index [ CDAI ] score ) over time in patients initiating etanercept ( monotherapy or with methotrexate ) . CDAI remission ( CDAI≤2.8 ) and sustained remission ( ≥6 months ) were determined through year 3 by treatment group , study , time to remission , and disease severity . RESULTS Patients from TEMPO and RADIUS II who received etanercept monotherapy showed similar CDAI remission rates ( 39 % and 35 % , respectively , at 3 years ) . Among patients who received etanercept with methotrexate , remission rates were 54 % and 36 % , respectively . Remission occurred more rapidly in TEMPO than RADIUS II perhaps from differences in compliance , patient populations , or sequence of combination therapy initiation . Generally , more patients with lower baseline CDAI scores achieved remission than those with higher scores . Continued remission appeared more likely in patients achieving remission earlier in the course of their therapy ( 0-6 months ) . CONCLUSIONS Remission by year 3 in etanercept-treated ( with and without methotrexate ) patients with RA occurred in ≥35 % of patients in both an RCT ( TEMPO ) and a clinical practice setting ( RADIUS II ) , and more frequently in those with lower baseline disease severity . Patients with lower RA disease activity were more likely to reach remission . Continued remission may be more likely in patients who achieved remission earlier .
62427
Intervention_Pharmacological
etanercept monotherapy
62428
Intervention_Pharmacological
etanercept-treated
62429
Intervention_Pharmacological
Etanercept and Methotrexate
62430
Intervention_Pharmacological
etanercept ( monotherapy or with methotrexate
62431
Outcome_Physical
Remission in rheumatoid arthritis
62432
Outcome_Physical
time to remission
62433
Outcome_Physical
disease activity
62434
Outcome_Physical
CDAI remission
62435
Participant_Condition
rheumatoid arthritis
62436
Participant_Condition
etanercept-treated patients
62437
Participant_Condition
rheumatoid arthritis ( RA )
62438
Participant_Sample-size
n=682